Latest Regulatory Filings News

Black Dragon Gold has withdrawn its application to classify the Salave Gold Project as a Project of Strategic Interest in Asturias, Spain, planning a stronger resubmission backed by legal clarity and community support.

Locate Technologies has dispatched its Scheme Booklet to shareholders, outlining the proposed acquisition by Locate NZ and urging a vote in favour at the upcoming virtual meeting.

Tissue Repair Limited reports steady progress in its Phase 3 clinical trials for chronic wound treatment and advances regulatory filings for its TR Pro+® product, while gearing up for a major commercial rollout in early 2026.

Neurizon Therapeutics has secured FDA clearance to resume clinical trials for its lead ALS drug NUZ-001, alongside a $5.2 million capital raise and a key licensing deal with Elanco Animal Health. These developments position the company for a critical growth phase in neurodegenerative disease therapeutics.

Helia Group’s 3Q25 APRA data reveals rising gross written premiums despite government scheme pressures, while a Board review confirms strategic focus on the Australian LMI market with significant cost cuts.

Optiscan Imaging Ltd secured $17.75 million in a fully underwritten equity raise, fueling clinical studies and regulatory preparations for its innovative medical imaging devices. The company also reported progress in international trials and strengthened its cash position to nearly $20 million.

Arovella Therapeutics has secured encouraging feedback from the US FDA on reagent testing for its CAR-iNKT cell therapy, setting the stage for an IND filing this quarter and clinical trials in early 2026.

Premier1 Lithium Limited’s PLCO securities have been suspended from trading due to regulatory non-compliance, raising questions about the company’s next steps and market impact.

Aguia Resources Limited’s AGRO securities have been suspended from trading by ASX Compliance, pending regulatory compliance. The move raises questions about the company’s current standing and next steps.

Firebrick Pharma reports a $1.94 million cash reserve after a $1.4 million placement, supporting expanded Nasodine sales across Southeast Asia and the US. Board changes and increased operational costs mark a pivotal quarter for the pharmaceutical innovator.

Imricor Medical Systems made significant regulatory strides with FDA submissions for its MRI-guided cardiac ablation devices and launched NorthStar commercially in Europe, even as it reported increased cash outflows in Q3 CY25.

Imagion Biosystems has made significant strides toward filing an IND application for its MagSense® HER2 breast cancer imaging agent, supported by positive FDA feedback and a recent $3.5 million capital raise to fund upcoming clinical trials.